Advertisement
CAMBRIDGE, Mass., March 29, 2017 /PRNewswire/ -- The future treatment of atopic dermatitis got a whole lot brighter yesterday with the approval of Sanofi-Regeneron's Dupixent, the first highly anticipated biologic to be approved for the disease.
According to the responses of 107 dermatologists in clinical practice fielded just one week ago (March 22-23), they are more than ready to begin using Dupixent when it becomes available later this week. More than a quarter of those surveyed already have a patient in mind and close to 80% agree that the availability of this new agent will lead to a significant improvement in patient outcomes.
Atopic dermatitis has consistently been rated as an area of high unmet need by dermatologists with more than half of the patients being classified as having moderate-to-severe disease. Other approved treatment options, such as topical steroids and conventional systemics, are described as having weak efficacy and numerous tolerability issues. This has led to a highly prevalent use of off-label drugs – more than half of the surveyed dermatologists report experience with Celgene's Otezla, more than a third have tried anti-TNF agents and over a quarter report using one of the new IL-17 inhibitors (Novartis' Cosentyx, Lilly's Taltz) in an attempt to manage the disease.
At the mild-to-moderate end of the spectrum, newly introduced EUCRISA from Pfizer is also shifting the treatment paradigm. More than half of the surveyed dermatologists have already prescribed the drug, although enthusiasm is more muted with only 20% of the users rating their satisfaction as high and only 33% describing EUCRISA as a significant advance over other topical agents. That being said, 80% of the survey respondents do anticipate starting new patients on the drug in the next three months, albeit among concerns of high out of pocket costs to patients and still-spotty reimbursement.
RealTime Dynamix: Atopic Dermatitis is an independent report series published each quarter. The series tracks the evolution of the AD market, provides a deep dive on launch effectiveness and highlights opportunities for pipeline agents. The next wave of research will be fielded in June 2017 and will reveal whether Sanofi-Regeneron can turn intent into outcome with the DUPIXENT launch.
About Spherix Global Insights Spherix Global Insights is a business intelligence and market research company specializing in renal, autoimmune, neurologic and rare disease markets. We provide clients with strategic insights leveraged from our independent studies conducted with healthcare providers and other stakeholders.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:Robbie McCarthy, Chief Strategy OfficerEmail: [email protected] Phone: 1-800-661-0571
Advertisement
According to the responses of 107 dermatologists in clinical practice fielded just one week ago (March 22-23), they are more than ready to begin using Dupixent when it becomes available later this week. More than a quarter of those surveyed already have a patient in mind and close to 80% agree that the availability of this new agent will lead to a significant improvement in patient outcomes.
Atopic dermatitis has consistently been rated as an area of high unmet need by dermatologists with more than half of the patients being classified as having moderate-to-severe disease. Other approved treatment options, such as topical steroids and conventional systemics, are described as having weak efficacy and numerous tolerability issues. This has led to a highly prevalent use of off-label drugs – more than half of the surveyed dermatologists report experience with Celgene's Otezla, more than a third have tried anti-TNF agents and over a quarter report using one of the new IL-17 inhibitors (Novartis' Cosentyx, Lilly's Taltz) in an attempt to manage the disease.
At the mild-to-moderate end of the spectrum, newly introduced EUCRISA from Pfizer is also shifting the treatment paradigm. More than half of the surveyed dermatologists have already prescribed the drug, although enthusiasm is more muted with only 20% of the users rating their satisfaction as high and only 33% describing EUCRISA as a significant advance over other topical agents. That being said, 80% of the survey respondents do anticipate starting new patients on the drug in the next three months, albeit among concerns of high out of pocket costs to patients and still-spotty reimbursement.
RealTime Dynamix: Atopic Dermatitis is an independent report series published each quarter. The series tracks the evolution of the AD market, provides a deep dive on launch effectiveness and highlights opportunities for pipeline agents. The next wave of research will be fielded in June 2017 and will reveal whether Sanofi-Regeneron can turn intent into outcome with the DUPIXENT launch.
About Spherix Global Insights Spherix Global Insights is a business intelligence and market research company specializing in renal, autoimmune, neurologic and rare disease markets. We provide clients with strategic insights leveraged from our independent studies conducted with healthcare providers and other stakeholders.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:Robbie McCarthy, Chief Strategy OfficerEmail: [email protected] Phone: 1-800-661-0571
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/pre-launch-intentions-for-sanofi-regenerons-dupixent-dupilumab-suggest-rapid-uptake-in-an-area-of-high-unmet-need-300431245.html
SOURCE Spherix Global Insights
